Effect of Daily Ingestion of Partially Hydrolyzed Guar Gum (PHGG) on Immune Function: A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study

Not Applicable

Completed

• Conditions: Healthy adults

• Registration Number: JPRN-UMIN000042753
• Lead Sponsor: Hokkaido Information University

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2020-12-15
• Study Completion: 2021-04-27
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Complete: follow-up complete
• Sex: All
• Target Recruitment: 100

Inclusion Criteria

Not provided

Exclusion Criteria

1. Subjects who are under treatment or medication for autoimmune diseases, chronic inflammatory diseases or allergies. 2. Subjects who plan to receive influenza vaccination from the screening test date to the end of intake. 3. Subjects with serious cerebrovascular, cardiac, hepatic, renal, gastrointestinal or affected with infectious diseases which is required to report to the authorities. 4. Subjects who have a major surgical history such as gastrectomy, gastrorrhaphy, enterectomy or other serious gastrointestinal surgeries. 5. Subjects with unusually high and/or low blood pressure, abnormal physical data and/or abnormal hematological data. 6. Subjects with severe anemia. 7. Pre- or post-menopausal women complaining of obvious physical changes. 8. Subjects who are at risk of having allergic reactions to drugs, foods (especially soybeans or peanuts) and/or birch pollen. 9. Subjects who regularly take medicines (Antibiotics, immunosuppressants, anti-inflammatory drugs, antirheumatic drugs, antihistamines, antiallergic drugs, lactic acid bacteria preparations), functional food and/or supplements (mushrooms, seaweed, nucleic acids, yeast, lactobacillus, etc.) which would affect the immune function. 10. Heavy smokers, alcohol addicts or subjects with irregular lifestyle. 11. Subjects who donated either 400 ml whole blood within 16 weeks (women), 12 weeks (men), 200 ml whole blood within 4 weeks, or blood components within 2 weeks, prior to the current study. 12. Pregnant or lactating women or women who expect to be pregnant during this study. 13. Subjects who currently participate in other clinical trials, or participated within the last 4 weeks prior to the current study. 14. Subjects determined to be ineligible by the principal investigator.

Study & Design

• Study Type: Interventional
• Study Design: Not specified